Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
Open Access
Abstract
Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimination of HCV. The recent failure of the first vaccine efficacy trial for the prevention of chronic HCV confirmed suspicions that this virus will be a challenging vaccine target. Here, we examine the published data from this first efficacy trial along with the earlier clinical and pre-clinical studies of the vaccine candidate and then discuss three key research directions expected to be important in ongoing and future HCV vaccine development. These include the following: 1. design of novel immunogens that generate immune responses to genetically diverse HCV genotypes and subtypes, 2. strategies to elicit broadly neutralizing antibodies against envelope glycoproteins in addition to cytotoxic and helper T cell responses, and 3. consideration of the unique immunological status of individuals most at risk for HCV infection, including those who inject drugs, in vaccine platform development and early immunogenicity trials.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI096882, R01AI126890, U01AI131313)
This publication has 183 references indexed in Scilit:
- Opioid Drug Abuse and Modulation of Immune Function: Consequences in the Susceptibility to Opportunistic InfectionsJournal of Neuroimmune Pharmacology, 2011
- Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural ProteinsGastroenterology, 2010
- Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsVaccine, 2010
- Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeysNature Medicine, 2010
- Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeysNature Medicine, 2010
- Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent ReinfectionGastroenterology, 2010
- More Rare Birds, and the Occasional SwanGastroenterology, 2009
- Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C VirusGastroenterology, 2009
- Potential impact of vaccination on the hepatitis C virus epidemic in injection drug usersEpidemics, 2009
- Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis CProceedings of the National Academy of Sciences, 2007